RAPS RAC-US Dumps Questions [2025] Pass for RAC-US Exam
Updated RAPS Study Guide RAC-US Dumps Questions
NEW QUESTION # 33
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?
- A. Contact the legal department and ask them how to proceed.
- B. Resubmit the entire package.
- C. Inform upper management immediately.
- D. Verify the procedure in the regulation for the corrections.
Answer: D
NEW QUESTION # 34
During a regulatory authority inspection of a manufacturing site, the inspector observes that one of the medicinal products manufactured at the site is not GMP compliant. The product
Is distributed globally.
Which of the following is the most appropriate action to take FIRST?
- A. Assess the potential safety risk.
- B. Withdraw the affected product from the markets.
- C. Send a "Dear Dr." letter to customers.
- D. Notify the global regulatory authorities.
Answer: D
NEW QUESTION # 35
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control activities for a medical device?
- A. Fault tree analysis
- B. Quality by design analysis
- C. Fishbone analysis
- D. Failure modes, effects, and criticality analysis
Answer: D
NEW QUESTION # 36
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Frequent communication
- B. Early collaboration
- C. Documented agreement
- D. Follow-up meeting after submission
Answer: A
NEW QUESTION # 37
A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?
- A. File patents of interest in target countries.
- B. File design patents in target countries.
- C. Use the community patent system.
- D. Use the Madrid system.
Answer: A
NEW QUESTION # 38
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject is hospitalized for the purpose of product administration.
- B. Subject is hospitalized due to complications of the product administration.
- C. Subject's hospitalization is due to an unscheduled hip operation.
- D. Subject's hospitalization is prolonged during the clinical trial.
Answer: A
NEW QUESTION # 39
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Proposed product route and frequency of administration
- B. Immunochemical and functional tests
- C. Proposed dose and volume of administration
- D. Biological activity with species and/or tissue specificity
Answer: D
NEW QUESTION # 40
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?
- A. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."
- B. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."
- C. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
- D. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
Answer: A
NEW QUESTION # 41
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Document and perform audits.
- B. Request documentation from the sub-contractor.
- C. Ask the vendor to take responsibility.
- D. Request an inspection from a regulatory authority.
Answer: A
NEW QUESTION # 42
The regulatory authority in Country X issued a request for a mandatory product recall in
Country X due to serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in
Country Y?
- A. Draft a formal letter to customers in Country Y about this recall.
- B. Review alt distribution records and complaints reported in Country Y.
- C. Initiate a mandatory recall of the product in Country Y.
- D. Prepare the legal team in Country Y for possible litigations.
Answer: B
NEW QUESTION # 43
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class D
- B. Class B
- C. Class A
- D. Class C
Answer: D
NEW QUESTION # 44
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Send a letter of complaint to the Ethics Committee that approved the site.
- B. Terminate the PI and inform the regulatory authorities.
- C. Increase the frequency of monitoring visits.
- D. Inform the institution that granted a medical license to the Pi.
Answer: B
NEW QUESTION # 45
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Reformulate the products with a replacement material.
- B. Review the company's existing Quality Management System
- C. Qualify another supplier and execute a supplier agreement.
- D. Complete a gap analysis to identify options.
Answer: C
NEW QUESTION # 46
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- B. Apply for review of the additional part of the product as a pharmaceutical product in Country
- C. Submit the product for review as a pharmaceutical product in Country Y.
- D. Examine decisions made about similar products in Country Y to propose the classification of the product.
Answer: B
NEW QUESTION # 47
Which of the following BEST describes the purpose of the ICH?
- A. To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions
- B. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions
- C. To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions
- D. To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions
Answer: B
NEW QUESTION # 48
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is a guaranteed cure for arthritis."
- B. "Product X is effective in all patients with arthritis."
- C. "Product X is safe for arthritis and without side effects."
- D. "Product X is effective for the treatment of arthritis."
Answer: D
NEW QUESTION # 49
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Relevance to regulations
- B. Scope and level of detail
- C. Revision history
- D. Expiration date
Answer: A
NEW QUESTION # 50
A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?
- A. For at least two years after the last approval of an application in an ICH region
- B. Three years after the last clinical study site was supplied with investigational drugs
- C. For a minimum of 10 years after completion of the clinical study
- D. Until the product has been discontinued from marketing in all ICH regions
Answer: A
NEW QUESTION # 51
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Allow the auditor accompanied access to the room to retrieve the records.
- B. Allow the auditor access to the room and records due to the current audit.
- C. Deny the auditor access to the room and retrieve only the requested records.
- D. Deny the auditor access to the room and records due to confidentiality concerns.
Answer: A
NEW QUESTION # 52
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
- A. Product registration
- B. Product stability
- C. Product requirements
- D. Product formulation
Answer: B
NEW QUESTION # 53
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?
- A. Before the enactment of the regulation, through the industry representative
- B. After the enactment of the regulation, through the industry representative
- C. Before the enactment of the regulation, through formal comments gathering process
- D. After the enactment of the regulation, through a product-specific meeting
Answer: C
NEW QUESTION # 54
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. List of lECs or lRBs
- B. Detailed CV of all investigators
- C. Protocol and protocol amendments
- D. Randomization scheme and codes
Answer: B
NEW QUESTION # 55
Which of the following BEST describes the process of post-marketing surveillance for healthcare products?
- A. Vigilance procedure to ensure the full traceability of the products
- B. Systematic procedure to review published scientific journals
- C. Vigilance procedure to notify the regulatory authorities about serious incidents
- D. Systematic procedure to review experiences with the products in use
Answer: A
NEW QUESTION # 56
Under which of the following circumstances would a regulatory authority require a more detailed premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data than would normally apply to an IVD device of that risk class?
- A. The device incorporates well-established technology that is already present in the market.
- B. The manufacturer's experience level with the type of IVD medical device is limited.
- C. Internationally recognized standards are available to cover the main aspects of the device and have been used by the manufacturer.
- D. The device is an updated version of a compliant device from the same manufacturer and contains no substantive change.
Answer: B
NEW QUESTION # 57
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product better than currently available alternatives?"
- C. "Is the product an established gold standard?"
- D. "Is the product profitable for the manufacturer?"
Answer: B
NEW QUESTION # 58
......
The RAC-US certification is an important credential for regulatory professionals in the United States who are looking to advance their careers and demonstrate their expertise in regulatory affairs. Regulatory Affairs Certification (RAC) US certification is recognized globally and provides a competitive advantage in the job market.
The RAPS RAC-US exam covers the development and approval of pharmaceuticals and medical devices, including the clinical trial process, the regulatory requirements for different types of products, and the various stages of the approval process. This section also covers the requirements for post-market surveillance and reporting, as well as the different types of post-market activities that may be required.
The RAC-US exam covers various topics, including regulatory strategy and intelligence, product development, clinical research, quality assurance and control, and post-marketing surveillance. It is designed to test the candidate's understanding of the U.S. regulatory environment, including the U.S. Food and Drug Administration (FDA) regulations and guidelines. RAC-US exam is created and administered by the Regulatory Affairs Professionals Society (RAPS), a global organization dedicated to advancing the regulatory profession and providing education and training in regulatory affairs.
Achieve Success in Actual RAC-US Exam RAC-US Exam Dumps: https://testking.vceprep.com/RAC-US-latest-vce-prep.html